Skip to main content
NCBI home page
British Journal of Pharmacology logoLink to British Journal of Pharmacology
. 1973 Jan;47(1):77–84. doi: 10.1111/j.1476-5381.1973.tb08160.x

Effects of enzyme inhibitors of catecholamine metabolism and of haloperidol on the pancreatic secretion induced by L-DOPA and by dopamine in dogs

Y Furuta, K Hashimoto, K Iwatsuki, O Takeuchi
PMCID: PMC1776517  PMID: 4717022

Abstract

1. Effects of inhibitors of DOPA decarboxylase, dopamine β-hydroxylase and monoamine oxidase, and haloperiodol on the secretion of pancreatic juice induced by L-DOPA and dopamine were studied in preparations of the isolated blood-perfused canine pancreas.

2. The increased secretion induced by the infusion of L-DOPA (100 μg/min) was completely antagonized by Ro 4-4602 (300 μg), a DOPA decarboxylase inhibitor.

3. The secretogogue effect of dopamine (1-10 μg) intra-arterially was not affected by Ro 4-4602, but was enhanced by the infusion of fusaric acid (100 μg/min), a dopamine β-hydroxylase inhibitor.

4. The increase in the secretion induced by dopamine (1-10 μg) was enhanced by treatment with nialamide (100 mg/kg), a monoamine oxidase inhibitor, given intravenously.

5. Haloperidol (1 mg) intra-arterially attenuated the dopamine-induced pancreatic secretion.

6. It is concluded that L-DOPA is converted to dopamine in the acinar cells which causes an increase in the secretion of pancreatic juice, thus the intracellular level of dopamine may be controlled by enzymatic equilibrium.

Full text

PDF
77

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Alm P., Ehinger B., Falck B. Histochemical studies on the metabolism of L-DOPA and some related substances in the exocrine pancreas. Acta Physiol Scand. 1969 May-Jun;76(1):106–120. doi: 10.1111/j.1748-1716.1969.tb04455.x. [DOI] [PubMed] [Google Scholar]
  2. Alm P., Ehinger B., Falck B., Nordgren L. Effects of reserpine and prenylamine on the L-dopa turnover in the rat exocrine pancreas. Eur J Pharmacol. 1971 Oct;16(2):192–200. doi: 10.1016/0014-2999(71)90010-0. [DOI] [PubMed] [Google Scholar]
  3. BLASCHKO H. Amine oxidase and amine metabolism. Pharmacol Rev. 1952 Dec;4(4):415–458. [PubMed] [Google Scholar]
  4. Brooks H. L., Stein P. D., Matson J. L., Hyland J. W. Dopamine-induced alterations in coronary hemodynamics in dogs. Circ Res. 1969 May;24(5):699–704. doi: 10.1161/01.res.24.5.699. [DOI] [PubMed] [Google Scholar]
  5. GLENNER G. G., BURTNER H. J., BROWN G. W., Jr The histochemical demonstration of monoamine oxidase activity by tetrazolium salts. J Histochem Cytochem. 1957 Nov;5(6):591–600. doi: 10.1177/5.6.591. [DOI] [PubMed] [Google Scholar]
  6. Hashimoto K., Sato S., Takeuchi O. Effect of dopamine on pancreatic secretion in the dog. Br J Pharmacol. 1971 Dec;43(4):739–746. doi: 10.1111/j.1476-5381.1971.tb07209.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Hidaka H., Nagatsu T., Takeya K., Takeuchi T., Suda H. Fusaric acid, a hypotensive agent produced by fungi. J Antibiot (Tokyo) 1969 May;22(5):228–230. doi: 10.7164/antibiotics.22.228. [DOI] [PubMed] [Google Scholar]
  8. Hornykiewicz O. Dopamine (3-hydroxytyramine) and brain function. Pharmacol Rev. 1966 Jun;18(2):925–964. [PubMed] [Google Scholar]
  9. McNay J. L., Goldberg L. I. Comparison of the effects of dopamine, isoproterenol, norepinephrine and bradykinin on canine renal and femoral blood flow. J Pharmacol Exp Ther. 1966 Jan;151(1):23–31. [PubMed] [Google Scholar]
  10. PORTER C. C., WATSON L. S., TITUS D. C., TOTARO J. A., BYER S. S. Inhibition of DOPA decarboxylase by the hydrazino analog of alpha-methylDOPA. Biochem Pharmacol. 1962 Nov;11:1067–1077. doi: 10.1016/0006-2952(62)90166-1. [DOI] [PubMed] [Google Scholar]
  11. Petkov P. De l'activité monoaminooxydasique dans le pancréas de l'homme et de certains mammifères: rat blanc, cobaye, chat et lapin. Ann Histochim. 1965 Jan-Mar;10(1):17–24. [PubMed] [Google Scholar]
  12. SCHUEMANN H. J., HELLER I. [On the hydroxytyramine content of organs]. Naunyn Schmiedebergs Arch Exp Pathol Pharmakol. 1959;236:474–482. [PubMed] [Google Scholar]
  13. Symchowicz S., Korduba C., Veals J., Tabachnick I. I. Norepinephrine biosynthesis in the rat pancreas. Biochem Pharmacol. 1968 Nov;17(11):2313–2317. doi: 10.1016/0006-2952(68)90039-7. [DOI] [PubMed] [Google Scholar]
  14. WEST G. B. 5-Hydroxytryptamine and hyperglycaemia. Nature. 1958 Jul 19;182(4629):182–182. doi: 10.1038/182182a0. [DOI] [PubMed] [Google Scholar]
  15. Yeh B. K., McNay J. L., Goldberg L. I. Attenuation of dopamine renal and mesenteric vasodilation by haloperidol: evidence for a specific dopamine receptor. J Pharmacol Exp Ther. 1969 Aug;168(2):303–309. [PubMed] [Google Scholar]

Articles from British Journal of Pharmacology are provided here courtesy of The British Pharmacological Society

RESOURCES